← Back to Clinical Trials
Recruiting NCT06759116

NCT06759116 Comparison Between Fentanyl and Dexmedetomidine As Adjuvant to Bupivacaine in Combined IPACK and Adductor Canal Block for Postoperative Analgesia After Knee Surgeries

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06759116
Status Recruiting
Phase
Sponsor Zagazig University
Condition Analgesia, Postoperative
Study Type INTERVENTIONAL
Enrollment 111 participants
Start Date 2025-01-10
Primary Completion 2025-07-10

Eligibility & Interventions

Sex All sexes
Min Age 21 Years
Max Age 85 Years
Study Type INTERVENTIONAL
Interventions
Control groupFentanyl groupDexmedetomidine group

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 111 participants in total. It began in 2025-01-10 with a primary completion date of 2025-07-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study will be undertaken to compare the analgesic effects of of fentanyl versus dexmedetomidine as adjuvant to bupivacaine in combined IPACK and ACB for pain management after total knee arthroplasty.

Eligibility Criteria

Inclusion Criteria: 1 - Patient acceptance 2. Cooperative patients 3. Age: ≥21 and 85\< years' old 4. Sex: both sexes (males or females). 5. Physical status: ASA Ι \& II\& Ш. 6. Body Mass Index (BMI): ≤ 35 kg/m2. 7. Type of operation: elective unilateral knee surgeries (TKA, ACL, knee arthroscopy) Exclusion Criteria: . Patient with any contraindications of regional blocks (as coagulopathy or local infection at injection site) 2. Patients with known history of allergy to the study drugs (bupivacaine, dexmedetomidine and fentanyl). 3\. Advanced hepatic, renal, cardiovascular, neurologic and respiratory diseases. 4.Chronic opioid use (more than 3 months or daily oral morphine \> 5 mg /day for 1 month) \-

Contact & Investigator

Central Contact

Dina Sadek Salem, MD

✉ sherifelagamy@yahoo.com

📞 01099333513

Frequently Asked Questions

Who can join the NCT06759116 clinical trial?

This trial is open to participants of all sexes, aged 21 Years or older, up to 85 Years, studying Analgesia, Postoperative. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06759116 currently recruiting?

Yes, NCT06759116 is actively recruiting participants. Contact the research team at sherifelagamy@yahoo.com for enrollment information.

Where is the NCT06759116 trial being conducted?

This trial is being conducted at El Sharkia, Egypt.

Who is sponsoring the NCT06759116 clinical trial?

NCT06759116 is sponsored by Zagazig University. The trial plans to enroll 111 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology